| __timestamp | Mesoblast Limited | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 54170000 | 59644696 |
| Thursday, January 1, 2015 | 65378000 | 79541000 |
| Friday, January 1, 2016 | 52263000 | 98015000 |
| Sunday, January 1, 2017 | 35072000 | 103958000 |
| Monday, January 1, 2018 | 27415000 | 103654000 |
| Tuesday, January 1, 2019 | 36983000 | 128951000 |
| Wednesday, January 1, 2020 | 50918000 | 135799000 |
| Friday, January 1, 2021 | 63586000 | 149883000 |
| Saturday, January 1, 2022 | 57967000 | 220206000 |
| Sunday, January 1, 2023 | 53107000 | 265542000 |
| Monday, January 1, 2024 | 23626000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing operational costs is crucial for success. Mesoblast Limited and Travere Therapeutics, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Mesoblast's SG&A expenses fluctuated, peaking in 2015 and 2021, before dropping significantly by 2024. In contrast, Travere Therapeutics experienced a steady increase, with expenses more than quadrupling from 2014 to 2023. This divergence highlights different strategic approaches: Mesoblast's focus on cost containment versus Travere's aggressive expansion. Notably, Travere's expenses surged by 50% from 2021 to 2023, reflecting its growth ambitions. As we look to 2024, Mesoblast's data is complete, while Travere's is yet to be revealed, leaving room for speculation on its future trajectory.
Selling, General, and Administrative Costs: Pfizer Inc. vs Mesoblast Limited
Who Optimizes SG&A Costs Better? Incyte Corporation or Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Mesoblast Limited
Cost Management Insights: SG&A Expenses for Opthea Limited and Mesoblast Limited
Cost Management Insights: SG&A Expenses for Axsome Therapeutics, Inc. and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of Veracyte, Inc. and Travere Therapeutics, Inc.
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Mesoblast Limited vs Novavax, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Mesoblast Limited vs Galapagos NV
Iovance Biotherapeutics, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.